引用文献についての表示-認知症有病率調査から見えた現状と課題-朝田 隆

引用文献についての表示-認知症有病率調査から見えた現状と課題-朝田 隆

学会や研究会で発表する先生は図表などを提示するときは引用文献を名前と年だけでなく、

巻数、ページも記載すべきである。文献を不完全に提示する研究者は他の発表者で使用された文献を後で読むことをしない習慣なのだろうか?

アルツハイマー病研究会に参加したが、朝田教授の講演は引用文献も紹介され、勉強になった。

「認知症有病率調査から見えた現状と課題」朝田 隆

 

NeuroRacer 2013 Nature

http://www.nature.com/news/gaming-improves-multitasking-skills-1.13674

Gaming improves multitasking skills. Study reveals plasticity in age-related cognitive decline. (最後に紹介された文献であるが、オンライン脳トレーニングゲームが認知症の低下を減少させる)

 

AD: 70歳台から女性が増加、男性は横ばい

MCI: 60歳台から出現

 

PLASSMAN, Brenda L., et al. Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Annals of Internal Medicine, 2010, 153: 182-193. http://annals.org/article.aspx?articleid=745941

# 運動、認知トレーニングがADの予防に有効

 

BARNES, Deborah E.; YAFFE, Kristine. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. The Lancet Neurology, 2011, 10: 819-828.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647614/

# 危険因子を軽減すると、予防効果があり

# 社会交流と知的活動:ADの予防効果あり

“Low education contributed to the largest proportion of AD cases worldwide. Mechanistically, it is believed that education and mental stimulation throughout life may lower risk of AD and dementia by helping to build a “cognitive reserve” that enables individuals to continue functioning at a `normal’ level despite experiencing neurodegenerative changes.76 This theory is supported by neuropathological studies which show that many older adults with normal cognitive function meet neuropathological criteria for AD at autopsy.68”

# 運動の習慣;予防効果あり

有酸素運動:前頭葉機能を高める

J Intern Med 269:107

週3回 1回20~60分

 

Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011; 26 Suppl 3:321-9.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3343739/

 

# スペインColombia Medellin村の常染色体優性遺伝性ADに対する予防介入試験

Crenezumab:(Crenezumab is a humanized monoclonal antibody against human 1-40 and 1-42 Beta amyloid, which is being investigated as a treatment of Alzheimer’s disease. Crenezumab was developed by the Swiss-based biopharmaceutical company AC Immune, which licensed the drug in 2006 to Genentech, Inc (http://en.wikipedia.org/wiki/Crenezumab)

http://www.clinicaltrials.gov/ct2/show/NCT01998841

A Study of Crenezumab Versus Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer Disease, Including a Placebo-Treated Noncarrier Cohort.

http://www.nytimes.com/2012/05/16/health/research/prevention-is-goal-of-alzheimers-drug-trial.html?pagewanted=all&_r=0

New Drug Trial Seeks to Stop Alzheimer’s Before It Starts

http://jama.jamanetwork.com/article.aspx?articleid=1861119

Researchers Test Strategies to Prevent Alzheimer Disease

“ In the first trial, begun last year by API and set to run 5 years, Reiman and colleagues are collaborating with a Colombian team headed by Francisco Lopera, MD, at the University of Antioquia, Medellín. For decades Lopera has focused his research efforts on a huge extended family living in the Abrurrá Valley, in the northern reaches of the Andes Mountains near Medellín. Among an estimated 5000 living members, about 1500 carry an autosomal-dominant mutation in the presenilin 1 (PSEN1) gene, one of 3 genes in which mutations are known to cause alterations in amyloid-beta processing that lead to early-onset AD.

 

The API researchers have amassed a registry with detailed cognitive assessments of more than 3400 members of this kindred, including more than 800 mutation carriers, who usually develop dementia before they turn 50 years old.

..

The API trial will enroll 300 cognitively healthy individuals who are at least 30 years of age from this family to test the antiamyloid monoclonal antibody crenezumab: 200 people with the mutation will be randomly assigned to receive injections of crenezumab or the placebo every 2 weeks for 260 weeks, while 100 noncarriers will also receive the placebo to ensure that study participants will not learn whether they carry the mutation. The vast majority of autosomal-dominant mutation carriers do not want to know their mutation status, noted Reiman.”

参考ブログ:crenezumab の苦悩(AD患者の母を介護している息子さん;詳細な記載とコメントがあり)

http://dislocon.blog.fc2.com/blog-entry-234.html

 

# amyloid-modifying monoclonal antibody solanezumab

Preventing Late-Onset Disease

“A third prevention trial,A4, focuses on a different, much more common group-older adults who are at risk for AD not because of an autosomal-dominant mutation but because their brain scans show evidence of amyloid accumulation (Sperling RA et al. Sci Transl Med. 2014; 6[228]:228fs13).

In this 3-year clinical trial, which began enrolling earlier this year at sites around the world, the researchers will equally randomize 1000 older individuals into placebo and treatment groups to test whether the amyloid-modifying monoclonal antibody solanezumab can slow the rate of cognitive decline on a composite measure of neuropsychological tests.”

 

中年期の肥満と老年期のやせは危険因子

高脂血症は老年期の認知機能維持に働く

(文献;フォローできず)

 

#「認知症予防戦略研究」H26年から5年間 1万人

 

#NeuroRacer 2013 Nature

http://www.nature.com/news/gaming-improves-multitasking-skills-1.13674

Gaming improves multitasking skills. Study reveals plasticity in age-related cognitive decline.

Brain HQ

https://itunes.apple.com/us/app/brainhq-brain-training-exercises/id537452201?mt=8

オンライン脳トレーニングゲーム

注意力にきく

http://blog.with2.net/link.php/36571

ブログランキングに登録しています。

 

 

 

 

 

marugametorao について

神経内科専門医 neurologist
カテゴリー: ニュースと政治, 神経内科医, 神経学, 健康, 医学, 医学教育, 挑戦 パーマリンク

コメントを残す

以下に詳細を記入するか、アイコンをクリックしてログインしてください。

WordPress.com ロゴ

WordPress.com アカウントを使ってコメントしています。 ログアウト / 変更 )

Twitter 画像

Twitter アカウントを使ってコメントしています。 ログアウト / 変更 )

Facebook の写真

Facebook アカウントを使ってコメントしています。 ログアウト / 変更 )

Google+ フォト

Google+ アカウントを使ってコメントしています。 ログアウト / 変更 )

%s と連携中